Program
3-(2-(4-quinolin-3-yl)benzyl-1-oxoisoindolin-6-yl)-N-hydroxy-acrylamide
Its studies are mostly in Hidradenitis Suppurativa · Crohn Disease, led by Shattuck Labs.
Drug page3-(2-(4-quinolin-3-yl)benzyl-1-oxoisoindolin-6-yl)-N-hydroxy-acrylamide: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shattuck Labs | 32 open or running | phase 2since Aug 4, 2026 | Aug 28, 2025 | Feb 2028phase 2 · NCT07934017 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 28, 2025First study: phase 1 study in Healthy VolunteersFirst studyNCT07158437 · 72 enrolled · United States
- Aug 4, 2026Phase 2 study in Crohn DiseasePhase 2 reachedNCT07753850 · 232 planned · United States
- Nov 6, 2026Phase 2 study in Hidradenitis SuppurativaNCT07934017 · 150 planned
Ahead
- Feb 2028Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07934017
- Jul 2028Primary completion: phase 2 study in Crohn DiseaseNCT07753850
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07934017Hidradenitis Suppurativa | 2 | Not yet recruiting | Feb 2028 | 150 |
| NCT07753850Crohn Disease · United States | 2 | Recruiting | Jul 2028 | 232 |
| NCT07158437Healthy Volunteers · United States | 1 | Completed | Jul 16, 2026 | 72 |
How it is read
Names in the registry
- “SL-325”, 3 entries
Conditions, from the studies’ own filings
- Hidradenitis Suppurativa, 1 study
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.